Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline
resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial …

Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …

Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

Background Among patients with metastatic pancreatic cancer, combination chemotherapy
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer …

The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and
management of adenocarcinomas of the exocrine pancreas and are intended to assist with …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …